Tirzepatide at maximum tolerated dose achieved 21.9% bodyweight reduction over 112 weeks
Trial shows tirzepatide helps maintain weight loss over two years
This Phase 3b randomized controlled trial evaluated tirzepatide in 378 adults with obesity over a 112-week period. Patients receiving the ma…
A long-term study shows that tirzepatide can help people with obesity maintain significant weight loss for up to 112 weeks.
Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventions
New analysis shows weight loss drugs and lifestyle changes affect muscle loss similarly
This systematic review and meta-analysis evaluated 15 782 adults with overweight or obesity receiving incretin-based therapies or intensive …
A large review of 15,782 adults found that weight loss drugs and lifestyle changes led to similar proportions of muscle loss during weight r…
Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
New analysis shows GLP-1 drugs cut stroke risk for people with leg artery disease
This systematic review and meta-analysis of over 240,000 adults with peripheral artery disease found that GLP-1 receptor agonists significan…
A large review of real-world data found GLP-1 drugs significantly reduce stroke and heart attack risk in adults with peripheral artery disea…
Tirzepatide improves waist-to-height ratio in adults with obesity or overweight
Tirzepatide improves waist-to-height ratio in obesity and prediabetes
A post-hoc analysis of a Phase 3 RCT found that tirzepatide (10/15 mg) improved waist-to-height ratio (WHtR) in adults with obesity or overw…
A new analysis finds tirzepatide helps more people with obesity achieve a healthier waist-to-height ratio, a key measure of belly fat risk.
Systematic review and meta-analysis of tirzepatide effects on HbA1c and weight in adults with type 2 diabetes
Tirzepatide lowers blood sugar and weight in real-world diabetes care
This systematic review and meta-analysis pooled data from real-world studies involving 89 296 adults with type 2 diabetes. Tirzepatide was a…
A large review of real-world data shows tirzepatide lowers blood sugar and helps people lose weight, matching results from clinical trials.
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
New Weight Loss Drug Beats Popular Options in Head-to-Head Comparison
This Bayesian network meta-analysis synthesized evidence from 42 randomized controlled trials, six of which were included in the network, to…
A newer weight loss drug helped people drop nearly 14 percent of their body weight, beating two popular options in a major comparison.
Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
New Weight Loss Pill Matches Surgery Results Without the Scalpel
A network meta-analysis of 14,293 adults with obesity found that tirzepatide 10 or 15 mg and sleeve gastrectomy achieved similar weight loss…
A diabetes drug now pulls even with stomach surgery for weight loss offering hope to millions who dread going under the knife but it is not …
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
CPAP and weight-loss drugs show different benefits for sleep apnea patients
This network meta-analysis of 3964 adults with obstructive sleep apnea found that CPAP produced the largest reduction in apnea-hypopnea inde…
A large analysis found CPAP best for breathing control, while weight-loss drugs improved body weight and blood sugar levels in sleep apnea p…
Tirzepatide improves standard and intensive therapeutic target attainment versus semaglutide in adults with type 2 diabetes
New drug helps more patients hit four key health goals at once
This post hoc analysis of a randomised phase 3 study included 1879 adults with type 2 diabetes followed for 40 weeks.
A new diabetes medicine helps more people hit their blood sugar, weight, and blood pressure goals at the same time
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
Network Meta-Analysis Finds Tirzepatide and Semaglutide Most Effective for Weight Loss in Adults
New Weight Loss Drugs Protect Your Heart and Lower Death Risk
A systematic review and network meta-analysis of 63,909 adults found that all obesity medications produced greater weight loss than placebo.
New data from 66 trials shows top obesity drugs significantly reduce heart events and death while helping with liver and joint pain issues f…
All tirzepatide Articles
- Tirzepatide at maximum tolerated dose achieved 21.9% bodyweight reduction over 112 weeks
- Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventions
- Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
- Tirzepatide improves waist-to-height ratio in adults with obesity or overweight
- GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
- Systematic review and meta-analysis of tirzepatide effects on HbA1c and weight in adults with type 2 diabetes
- Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
- Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
- Tirzepatide improves standard and intensive therapeutic target attainment versus semaglutide in adults with type 2 diabetes
- CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
- Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
- Review of observational data links semaglutide and tirzepatide to survival in breast cancer
- Network Meta-Analysis Finds Tirzepatide and Semaglutide Most Effective for Weight Loss in Adults
- Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes
- Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
- Tirzepatide shows greater lean body mass loss than semaglutide in first-episode GLP-1RA users with type 2 diabetes
- Oral denatonium acetate (ARD-101) reduced weight versus placebo in adults with obesity over 28 days
- Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes
- Post hoc analysis links WHtR threshold to remission in obesity management with tirzepatide vs semaglutide
- Tirzepatide improves patient-reported physical function in adults with overweight or obesity